# A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

> **NCT04687072** · PHASE3 · COMPLETED · sponsor: **argenx** · enrollment: 207 (actual)

## Conditions studied

- Primary Immune Thrombocytopenia

## Interventions

- **BIOLOGICAL:** Efgartigimod PH20 SC
- **OTHER:** Placebo PH20 SC

## Key facts

- **NCT ID:** NCT04687072
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-16
- **Primary completion:** 2023-10-09
- **Final completion:** 2023-10-09
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04687072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04687072, "A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04687072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*